Skip to main content
. 2011 Sep 30;6(9):e25787. doi: 10.1371/journal.pone.0025787

Figure 2. Serum microRNA levels in patients with renal cell carcinoma, benign renal tumors and healthy controls.

Figure 2

MicroRNAs were profiled in serum and tissue of patients with clear cell renal cell carcinoma (ccRCC) and healthy controls (each nā€Š=ā€Š6) using the TaqMan Low Density Array; 36 microRNAs were upregulated in RCC tissue and serum of RCC patients (Phase-1). Seven microRNAs were chosen for verification using real-time PCR in a cohort of 33 ccRCC and 30 healthy individuals (Phase-2). In Phase-3, the finding of increased serum miR-1233 levels in RCC patients was confirmed in a multicentre cohort of 84 RCC, 93 healthy and 13 benign renal tumors (BRT). MicroRNA recovery (as determined using quantification of the synthetic miR-39) was similar in the study centers (UKB, UKM, UKS); the level of miR-1233 were somewhat higher in patients from UKM.